GlassScriptPhysician profile
Stanislav Meyler
NPI 1942465174
$9,487.82
in general payments reported to CMS, 2019-2025
28 companies · $1,948 in 2025
The $1,948 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,659 · 2022: $2,156 · 2023: $1,858 · 2024: $1,868 · 2025: $1,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,499 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,499.49 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,563.43 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $1,346.37 | 2021-2025 | |
| Abbvie INC. | $1,261.00 | 2021-2025 | |
| Lilly USA, LLC | $986.98 | 2021-2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $952.82 | 2021-2025 | Acthar |
| Amgen INC. | $593.25 | 2021-2025 | Krystexxa, Enbrel, Otezla |
| Astrazeneca Pharmaceuticals LP | $535.14 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $456.21 | 2021-2024 | Benlysta, Nucala |
| Horizon Therapeutics Plc | $356.45 | 2021-2023 | Krystexxa |
| Ucb, INC. | $230.01 | 2021-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $214.64 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $142.49 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $131.31 | 2021-2025 | Sotyktu |
| Ani Pharmaceuticals, INC. | $113.58 | 2023 | Purified Cortrophin Gel |
| Sk Life Science, INC. | $99.64 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $89.95 | 2025 | |
| Nestle Healthcare Nutrition INC. | $74.03 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.96 | 2024-2025 | Cyltezo |
| Hikma Pharmaceuticals USA | $54.73 | 2021-2022 | |
| Madrigal Pharmaceuticals | $31.57 | 2025 | Rezdiffra |
| Tersera Therapeutics LLC | $31.25 | 2023 | Quzyttir |
| Invivyd INC | $28.85 | 2025 | Pemgarda |
| Aurinia Pharma U.S., INC. | $24.97 | 2022 | |
| Acella Pharmaceuticals, LLC | $23.64 | 2025 | NP Thyroid 60 |
| Phadia US INC. | $23.17 | 2024 | Immunocap |
| Cumberland Pharmaceuticals, INC. | $21.18 | 2022 | |
| Vivus LLC | $20.76 | 2023 | Pancreaze |
| Oxford Immunotec USA INC | $18.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanislav Meyler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.